- MOMENTUM Phase 3 clinical trial for momelotinib underway, targeting enrolment of 180 patients with myelofibrosis who are symptomatic and anemic - - Publications highlighting durability, safety...
Sierra Oncology, Inc. (SRRA), a late-stage drug development company focused on the registration and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially...
-"Building MOMENTUM for Patients with Myelofibrosis" scheduled for 10:00 a.m. ET on March 4, 2020 - VANCOUVER, Feb. 25, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a late-stage drug development...
View all news releases
Building Momentum for Patients with Myelofibrosis – Q1 2020
View All Presentations
Location: Boston, MA
View all events and webcasts
James Smith, Vice President Corporate Affairs
Sign up for investor alerts